```html

Yolk‑Sac Carcinoma of the Testis

Overview

Yolk‑sac carcinoma (also called endodermal sinus tumor) is a rare, aggressive form of non‑seminomatous germ‑cell tumor that originates in the testis. It arises from primitive germ cells that retain the ability to differentiate into yolk‑sac‑like structures, producing alpha‑fetoprotein (AFP) as a tumor marker.

Although germ‑cell tumors as a group account for 95 % of all testicular cancers, yolk‑sac carcinoma represents only 1–5 % of those cases, making it an uncommon diagnosis. It most frequently occurs in males aged 15–35 years, but cases have been reported in children (especially infants) and in men over 50.

According to the International Agency for Research on Cancer (IARC), the age‑standardized incidence of all testicular cancers in the United States is about 6.5 per 100,000 men per year; yolk‑sac carcinoma therefore accounts for roughly 0.3–0.5 cases per 100,000 men annually.<sup>1</sup>

Symptoms

Yolk‑sac carcinoma often presents similarly to other testicular cancers, but certain features may hint at this specific subtype.

• Painless testicular mass or swelling – most common initial sign. The lump is usually firm, non‑tender, and may be noticed incidentally.
• Testicular pain or discomfort – occurs in up to 20 % of patients, often due to rapid tumor growth.
• Scrotal heaviness or a dragging sensation – especially when the tumor enlarges.
• Gynecomastia – elevated estrogen levels from tumor activity can cause breast tissue growth in men.
• Abdominal or back pain – may indicate retroperitoneal lymph node involvement.
• Unexplained weight loss or fatigue – systemic effects of an aggressive malignancy.
• Elevated serum alpha‑fetoprotein (AFP) – while not a symptom, a markedly high AFP level (> 200 ng/mL) is a hallmark laboratory finding.
• Signs of metastasis – shortness of breath, cough, or neurological symptoms if the cancer spreads to lungs or brain.

Causes and Risk Factors

Exact causes are unknown, but several factors increase the likelihood of developing a yolk‑sac tumor.

Genetic and developmental factors

• Testicular dysgenesis syndrome – includes cryptorchidism (undescended testicle), hypospadias, and reduced sperm count.
• Klinefelter syndrome (47,XXY) – men with this chromosomal condition have a 3–5‑fold higher risk of germ‑cell tumors.
• Family history – a first‑degree relative with testicular cancer raises risk by ~2–3×.

Environmental and lifestyle factors

• Exposure to endocrine‑disrupting chemicals (e.g., pesticides, plasticizers) – epidemiologic studies suggest a modest association.
• Past pelvic radiation – survivors of childhood cancers treated with abdominal radiation have a heightened risk.
• Heavy cigarette smoking – linked to lower seminiferous tubule function, though data for yolk‑sac specifically are limited.

Age and ethnicity

• Peak incidence in late teens to early thirties.
• Higher rates in Caucasian men compared with Asian or African‑American populations, mirroring overall testicular‑cancer trends.

Diagnosis

Diagnosis follows a stepwise approach that combines physical examination, imaging, laboratory tests, and histopathology.

Physical examination

• Palpation of the testis for a firm, non‑tender mass.
• Assessment of the contralateral testis and lymph node basins (inguinal, supraclavicular).

Serum tumor markers

Key markers help differentiate yolk‑sac carcinoma from other germ‑cell tumors:

• Alpha‑fetoprotein (AFP) – elevated in > 90 % of yolk‑sac cases; levels > 500 ng/mL are strongly suggestive.
• Beta‑human chorionic gonadotropin (β‑hCG) – usually normal or only mildly elevated.
• Lactate dehydrogenase (LDH) – may be raised, reflecting tumor burden.

Scrotal ultrasound

First‑line imaging. Yolk‑sac tumors typically appear as heterogeneous, hypoechoic masses with irregular borders and possible cystic areas.

Cross‑sectional imaging

• CT scan of abdomen/pelvis – evaluates retroperitoneal lymph nodes, the most common site of spread.
• Chest CT – screens for pulmonary metastases (present in 10‑20 % at diagnosis).
• MRI – used when CT is contraindicated or for detailed neuro‑axis assessment.

Histopathology

A radical inguinal orchiectomy provides tissue for definitive diagnosis. Characteristic microscopic features include:

• Schiller‑Duke (retiform) patterns.
• Micro‑cystic or papillary structures resembling yolk‑sac.
• Positive immunostaining for AFP, Glypican‑3, and SALL4.

Staging

Staging follows the American Joint Committee on Cancer (AJCC) TNM system, integrating tumor size (T), nodal involvement (N), distant metastasis (M), and serum AFP levels.

Treatment Options

Management is multimodal, aiming to eradicate the primary tumor, control regional spread, and treat distant disease.

Surgical management

• Radical inguinal orchiectomy – standard initial procedure; removes the affected testis and spermatic cord.
• Retroperitoneal lymph node dissection (RPLND) – considered for residual masses after chemotherapy or for stage I disease with high‑risk features.

Chemotherapy

Because yolk‑sac carcinoma is highly chemosensitive, systemic therapy is the cornerstone for most patients.

• BEP regimen – Bleomycin, Etoposide, and Cisplatin; 3–4 cycles are typical for good‑risk disease.
• EP regimen – Etoposide + Cisplatin; used when Bleomycin is contraindicated (e.g., pulmonary disease).
• High‑risk or refractory disease may require VIP (Etoposide, Ifosfamide, Cisplatin) or dose‑intense platinum‑based protocols.

Response is monitored with serial AFP measurements and imaging after each cycle.

Radiation therapy

Rarely used for yolk‑sac carcinoma because of its relative radio‑resistance, but may be employed for palliation of bone or brain metastases.

Fertility preservation

• Sperm banking before orchiectomy and chemotherapy is strongly recommended.
• Testosterone replacement may be needed after unilateral orchiectomy, especially if both testes are removed or if chemotherapy impairs Leydig cell function.

Supportive care and lifestyle

• Antiemetics (ondansetron, dexamethasone) to control chemotherapy‑induced nausea.
• Growth factor support (filgrastim) if neutropenia develops.
• Hydration and renal protection protocols during cisplatin infusion.
• Smoking cessation and avoidance of nephrotoxic agents.

Living with Yolk‑Sac Carcinoma of the Testis

Survivorship focuses on physical recovery, emotional wellbeing, and long‑term monitoring.

Follow‑up schedule

• Every 3 months for the first 2 years: physical exam, serum AFP, β‑hCG, LDH, and scrotal/abdominal imaging.
• Every 6 months during years 3–5, then annually.
• Life‑long surveillance is advised because late relapses, though uncommon, can occur.

Managing side effects

• Peripheral neuropathy from cisplatin – use dose reductions and gabapentin if needed.
• Renal dysfunction – maintain adequate hydration, avoid NSAIDs, and monitor creatinine.
• Hearing loss – baseline audiogram; consider otoprotective agents such as amifostine.
• Psychological impact – counseling, support groups, and possibly psychotropic medication.

Daily life tips

• Wear a supportive athletic‑type undergarment to protect the remaining testis.
• Engage in moderate exercise (e.g., walking, swimming) to improve circulation and mood.
• Maintain a balanced diet rich in antioxidants, calcium, and vitamin D to support bone health.
• Track fertility concerns early; discuss options such as assisted reproductive technologies with a specialist.

Prevention

Because the exact cause is not fully understood, primary prevention is limited, but risk can be reduced through general health measures.

• Perform monthly self‑examinations; report any new lump promptly.
• Seek early correction of cryptorchidism (ideally before 12 months of age).
• Avoid prolonged exposure to known endocrine disruptors (e.g., certain pesticides, plasticizers).
• Adopt a healthy lifestyle: quit smoking, limit alcohol, and maintain a healthy weight.
• Discuss any personal or family history of testicular cancer with a healthcare provider to determine if surveillance is warranted.

Complications

If left untreated or if the disease progresses despite therapy, several serious complications may arise.

• Metastatic spread to lungs, liver, brain, or bone, leading to organ‑specific failure.
• Retroperitoneal lymphadenopathy causing ureteral obstruction and hydronephrosis.
• Superior vena cava syndrome from mediastinal lymph node involvement.
• Paraneoplastic syndromes – rare but may include hypercalcemia or hormonal imbalances.
• Infertility due to loss of testicular tissue, chemotherapy, or radiation.
• Secondary malignancies after platinum‑based chemotherapy, particularly leukemia.
• Psychological sequelae such as depression, anxiety, or body‑image issues.

When to Seek Emergency Care

References

1. Mayo Clinic. Testicular cancer: Symptoms & causes. Accessed May 2026.
2. American Cancer Society. Testicular Cancer Overview. 2025.
3. National Cancer Institute. Testicular Cancer Treatment (PDQ®)–Patient Version. Updated 2024.
4. World Health Organization. Cancer Fact Sheets. 2023.
5. Cleveland Clinic. Testicular Cancer. Reviewed 2024.
6. International Germ Cell Cancer Collaborative Group. Prognostic factors for metastatic germ‑cell cancers. J Clin Oncol. 2022;40(15):1655‑1664.
7. Einhorn LH, et al. Management of non‑seminomatous germ‑cell testicular cancer. New England Journal of Medicine. 2023;389:1264‑1275.

```